Citius Pharmaceuticals Inc (NASDAQ:CTXR) does about 2.30M shares in volume on a normal day but saw 5148264 shares change hands in the recent trading day. The company now has a market cap of 168.46M USD. Its current market price is $0.93, marking an increase of 2.86% compared to the previous close of $0.91. The 52 week high reached by this stock is $1.07 whilst the lowest price level in 52 weeks is $0.48.
Citius Pharmaceuticals Inc (CTXR) has a 20-day trading average at $0.8574 and the current price is -12.86% off the 52-week high compared with 94.25% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.7150 and its 200-day simple moving average is $0.7449. If we look at the stock’s price movements over the week, volatility stands at 11.82%, which decreases to 10.98% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 63.97 to suggest the stock is neutral.
The consensus objective for the share price is $4.67, suggesting that the stock has a potential upside of 80.09% over the period.
1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 30, 2021 when Maxim Group initiated the stock to “Buy” and issued a price target of $4.
Citius Pharmaceuticals Inc (CTXR) stock is down -5.36% over the week and 76.19% over the past month. Its price is 23.25% year-to-date and -4.64% over the past year.
The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of -0.06 below consensus estimates by -0.01. The company’s next earnings report forecasts estimating quarterly EPS at -0.05 and -0.2 for whole year.
To reach the target analysts have set, the stock logically needs to grow 80.09 percent from here.
The company has a return on investment of -46.97% and return on equity of -42.44%. The forward price to earnings ratio is 13.99. The beta has a value of 1.63. Price to book ratio is 1.87.
